2-Dichlormethyl-pyrimidin | 54198-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Dichlormethyl-pyrimidin
• 英文别名: 2-dichloromethyl-pyrimidine；Dichlormethyl-pyrimidin；2-(dichloromethyl)pyrimidine
• CAS: 54198-87-7
• 化学式: C₅H₄Cl₂N₂
• 分子量: 163.006
• InChiKey: ZSMCTJFHKRMYPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS
  申请人：Alexander Christopher W.

  公开号：US20100144722A1

  公开（公告）日：2010-06-10

  Novel heterocyclic compounds, sstereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. Additionally, methods of forming novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided.

  提供了式(I)及其立体异构体和/或药学上可接受的盐的新型杂环化合物。此外，还提供了形成新型杂环化合物、其立体异构体和/或药学上可接受的盐的方法。
• Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer
  申请人：NAKAHARA Shinya

  公开号：US20090018012A1

  公开（公告）日：2009-01-15

  A process for producing an olefin copolymerization catalyst, comprising the step of contacting, with one another, (A) a solid catalyst component containing a titanium atom, a magnesium atom and a halogen atom, (B) an organoaluminum compound and/or organoaluminumoxy compound, and (C) a nitrogen-containing aromatic heterocyclic compound, whose one or more carbon atoms adjacent to its nitrogen atom are linked to an electron-withdrawing group, or a group containing an electron-withdrawing group; and a process for producing an olefin copolymer using the an olefin copolymerization catalyst.
• US7732540B2
  申请人：——

  公开号：US7732540B2

  公开（公告）日：2010-06-08
• [EN] HETEROCYCLIC COMPOUNDS AS GATA MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES COMME MODULATEURS DE GATA
  申请人：REDDYS LAB LTD DR

  公开号：WO2010028179A1

  公开（公告）日：2010-03-11

  Novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. Additionally, methods of forming novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided.